You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Real Time 3-D Modeling and Immersive Visualization for Enhanced Soldier Situation Awareness
SBC: Carnegie Robotics LLC Topic: A12aT003We propose a rapid mapping and 3-D visualization system especially suited for inside buildings, tunnels, urban canyons, and other environments where GPS may be poor or not available. The system--which was fully demonstrated in our Phase I effort-- includes mobile Sensor Nodes that wirelessly supply compressed 3D range data and color imagery to a central Fusion Node. The Fusion Node runs 3D recon ...
STTR Phase II 2014 Department of DefenseArmy -
Liquid Crystal-based Sensors for Detection of Airborne Toxic Chemicals for Integration with Unmanned Robotic Systems
SBC: Platypus Technologies, LLC Topic: A13AT004In Phase I we successfully reached all goals and milestones in developing liquid crystal sensors that detected 100 ppb of each of four target gases (DMMP, hydrogen sulfide, nitrogen dioxide and ammonia) within 60 seconds. In Phase II, we propose to expand this detection capability to a total of seven gases, adding volatile organic compounds, chlorine and half-mustard to the set. We then propose ...
STTR Phase II 2014 Department of DefenseArmy -
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIDESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Rapid, Accurate, and Low-Cost Stool Clostridium difficile Genetic Test
SBC: LENIMA FIELD DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): Clostridium difficile (CD) is a bacterium causing diarrhea and other intestinal problems linked to 14,000 annual deaths in the US. CDI is an antibiotic-associated infection as well as a health-care-associated infection.Current CDI diagnosis relies on CD toxins enzyme immunoassay (EIA) together with antigen (GDH) EIA. Although stool toxin EIA is specific and rel ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget
SBC: DOTY SCIENTIFIC, INC. Topic: NIA? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NIGMSDESCRIPTION: While HIV/AIDS can be managed with antiretroviral drugs that block viral replication, these agents do not clear the virus and require life-long drug administration with associated risks of cumulative toxicity and drug resistance. Recently, wediscovered a completely new class of compounds that interfere with the HIV-1 virulence factor, Nef. This viral protein is critical to HIV-1 repli ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NHLBIWe have discovered the first-ever inhibitors of PF4, a platelet protein central to the pathophysiology of heparin induced thrombocytopenia (HIT). Heparin is a naturally-occurring anticoagulant that prevents the formation of clots and extension of existingclots within the vasculature, and major medical applications of heparin include dialysis, cardiac catheterization, and cardiopulmonary bypass sur ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Wireless Device to Monitor and Track Fluid Consumption in At-Risk Older Adults
SBC: Smart Activity of Daily Living, LLC Topic: NINRDESCRIPTION (provided by applicant): The long term goal of the proposed project by Smart Activities of Daily Living, LLC (Smart ADLs) is to develop a device (the Smart Cup) that will improve the health of older adults by managing nutrition using smart health technology. Malnutrition (under nutrition) is a common geriatric syndrome found in older adults across the care continuum. Older adults accou ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing Intravesical Liposomes for Interstitial Cystitis
SBC: Lipella Pharmaceuticals Inc. Topic: NIDDKDESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. (Pittsburgh, PA) is a clinical-stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions. Lipella is submitting a research proposal to the Small Business Technology Transfer program titled Developing Intravesical Liposomes for Interstitial Cystitis . The project proposes to evaluate the sa ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re
SBC: Apogee Biotechnology Corporation Topic: 102DESCRIPTION provided by applicant Diffuse large B cell lymphoma DLBCL represents one of the most common variants of Non Hodgkinandapos s lymphoma NHL and oncogenic herpesviruses EBV and KSHV are the etiologic agents for the majority of these tumors in patients over or those infected with the human immunodeficiency virus HIV Despite modest improvements in outcomes for patients rece ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health